The potential use of Invokana (canagliflozin) for chronic kidney disease as well as type 2 diabetes, its current indicated use, attracted national headlines in mid-April. If Janssen Pharmaceuticals, Inc.’s supplemental indication for its medication is approved by the FDA, “it would be the first new treatment for diabetic kidney disease in decades,” the National Kidney Foundation said. Others see it as positive news, but one expert predicts Invokana may not find strong enthusiasm for this new use amid possible safety concerns and rival products likely to get similar indications.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.